Elevai Labs (ELAB) Competitors

$0.60
+0.02 (+3.45%)
(As of 04/23/2024 ET)

ELAB vs. MBRX, GHSI, TFFP, MTEM, AKTX, AEZS, HEPA, ADIL, CYCN, and VIRI

Should you be buying Elevai Labs stock or one of its competitors? The main competitors of Elevai Labs include Moleculin Biotech (MBRX), Guardion Health Sciences (GHSI), TFF Pharmaceuticals (TFFP), Molecular Templates (MTEM), Akari Therapeutics (AKTX), Aeterna Zentaris (AEZS), Hepion Pharmaceuticals (HEPA), Adial Pharmaceuticals (ADIL), Cyclerion Therapeutics (CYCN), and Virios Therapeutics (VIRI). These companies are all part of the "pharmaceutical preparations" industry.

Elevai Labs vs.

Moleculin Biotech (NASDAQ:MBRX) and Elevai Labs (NASDAQ:ELAB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

In the previous week, Moleculin Biotech and Moleculin Biotech both had 3 articles in the media. Elevai Labs' average media sentiment score of 0.28 beat Moleculin Biotech's score of 0.22 indicating that Moleculin Biotech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Moleculin Biotech
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Elevai Labs
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Moleculin Biotech's return on equity of 0.00% beat Elevai Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
Moleculin BiotechN/A -80.91% -67.69%
Elevai Labs N/A N/A N/A

Elevai Labs has higher revenue and earnings than Moleculin Biotech.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Moleculin BiotechN/AN/A-$29.77M-$13.64-0.34
Elevai Labs$1.71M6.07-$4.30MN/AN/A

15.5% of Moleculin Biotech shares are held by institutional investors. Comparatively, 22.2% of Elevai Labs shares are held by institutional investors. 6.7% of Moleculin Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Moleculin Biotech presently has a consensus price target of $35.00, suggesting a potential upside of 660.87%. Given Elevai Labs' higher possible upside, equities research analysts clearly believe Moleculin Biotech is more favorable than Elevai Labs.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Moleculin Biotech
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Elevai Labs
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Moleculin Biotech received 227 more outperform votes than Elevai Labs when rated by MarketBeat users.

CompanyUnderperformOutperform
Moleculin BiotechOutperform Votes
227
53.54%
Underperform Votes
197
46.46%
Elevai LabsN/AN/A

Summary

Moleculin Biotech and Elevai Labs tied by winning 5 of the 10 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ELAB vs. The Competition

MetricElevai LabsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$10.05M$6.48B$4.84B$7.49B
Dividend YieldN/A3.10%5.51%3.98%
P/E RatioN/A17.47240.8920.93
Price / Sales6.07314.822,419.7589.75
Price / CashN/A19.2532.1727.25
Price / Book2.735.624.684.31
Net Income-$4.30M$138.18M$102.52M$213.83M
7 Day Performance4.71%-0.10%0.41%1.35%
1 Month Performance-21.05%-8.53%-5.79%-4.08%
1 Year PerformanceN/A1.15%10.14%7.92%

Elevai Labs Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MBRX
Moleculin Biotech
2.1795 of 5 stars
$4.46
-3.7%
$35.00
+684.8%
-60.8%$9.95MN/A-0.3315Analyst Report
GHSI
Guardion Health Sciences
0 of 5 stars
$7.89
-0.1%
N/A+27.3%$10.15M$12.25M71.7312
TFFP
TFF Pharmaceuticals
1.306 of 5 stars
$3.52
-8.6%
$72.00
+1,945.5%
-81.5%$9.70M$730,000.00-0.2815Gap Up
MTEM
Molecular Templates
1.1867 of 5 stars
$1.78
-5.8%
N/A-76.0%$9.56M$57.31M-1.15111Gap Down
AKTX
Akari Therapeutics
0 of 5 stars
$1.20
-0.8%
N/A-72.5%$9.51MN/A0.0015Analyst Report
AEZS
Aeterna Zentaris
1.8019 of 5 stars
$1.95
-1.5%
$15.00
+669.2%
-36.2%$9.48M$4.50M-0.5711Analyst Report
HEPA
Hepion Pharmaceuticals
0.0248 of 5 stars
$2.18
-0.5%
N/A-89.6%$9.46MN/A0.0025Gap Up
ADIL
Adial Pharmaceuticals
0.7731 of 5 stars
$2.61
+12.0%
N/A-79.1%$9.45MN/A-0.4616Gap Down
CYCN
Cyclerion Therapeutics
0 of 5 stars
$3.44
+2.1%
N/A-53.5%$9.32M$1.62M-0.621Positive News
Gap Up
VIRI
Virios Therapeutics
0 of 5 stars
$0.47
-7.8%
N/A-36.6%$9.07MN/A-1.684Gap Down

Related Companies and Tools

This page (NASDAQ:ELAB) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners